Need professional-grade analysis? Visit stockanalysis.com
$166.82M
N/A
N/A
N/A
Nkarta Inc (NKTX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $3.32, down 4.32% from the previous close.
Over the past year, NKTX has traded between a low of $1.66 and a high of $3.47. The stock has gained 52.3% over this period. It is currently 100.0% above its 52-week low.
Nkarta Inc has a market capitalization of $166.82M.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Side-by-side comparison against top Healthcare peers.